ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Raub Corrects Record on ALERT

April 20, 1984

NIH Panel Calls for Further Research On End-of-Life Issues.

January 21, 2005

OMB Restrictions On Reprogramming Could Result In Inefficient Last Minute Spending By Institutes

September 13, 1985

FDA Proposes Office For Patients With Life Threatening Disease

November 13, 1992

Funding Opportunity: DOD Devotes $150 Million to Breast Cancer Research

August 5, 2011

NCI Awards $15M For Studies Of Glycobiology.

September 28, 2007